Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Patient Reported Outcome Measures × Breast × Clear all

Phase

Status

Recruiting 2 Active not recruiting 2 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Other neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 75 Cyclophosphamide 59 Capecitabine 59 Paclitaxel 54 Docetaxel 53 Letrozole 44 Fulvestrant 42 Carboplatin 37 Lapatinib 33 pembrolizumab 32 Doxorubicin 32 Vinorelbine 29 Bevacizumab 28 exemestane 25 Anastrozole 25 Tamoxifen 21 Gemcitabine 21 Albumin-Bound Paclitaxel 20 Radiotherapy 17 Taxes 16 pertuzumab 15 palbociclib 14 Everolimus 14 atezolizumab 13 Magnetic Resonance Spectroscopy 13 Epirubicin 13 130-nm albumin-bound paclitaxel 13 eribulin 12 Goserelin 12 Ado-Trastuzumab Emtansine 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05932667 2023-12-21

DEMETER

Institut Curie

Phase 2 Terminated

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡